Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus-Reference-Cited by-同舟云学术

Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus

Published:2020-01-01 Issue:1 Volume:22 Page:57-61
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Lucidi Paola¹,Porcellati Francesca¹,Cioli Patrizia¹,Candeloro Paola¹,Marinelli Andreoli Anna¹,Bolli Geremia B.¹,Fanelli Carmine G.¹

Affiliation:

1. Section of Endocrinology & Metabolism, Department of Medicine, Perugia University School of Medicine, Perugia, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2019.0231

Reference15 articles.

1. Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes

2. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

3. 4. Gosmanov NR, Gosmanov AR, Gerich JE: Glucagon physiology. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, eds. Endotext [Internet]. South Dartmouth, MA: MDText.com, Inc., 2000–2011.

4. Insulin Dose-Response Characteristics for Suppression of Glycerol Release and Conversion to Glucose in Humans

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The recent progress on nanomaterial-based chemosensors for diagnosis of human exhaled breath: a review;Journal of Materials Science;2024-05

2. Ketone Bodies in Diabetes Mellitus: Friend or Foe?;Nutrients;2023-10-16

3. Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes;Pediatric Drugs;2022-07-26

4. Interface for an App—The design rationale leading to an app that allows someone with Type 1 diabetes to self-manage their condition;Synthesis Lectures on Human-Centered Informatics;2021-06-09

5. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL−1 and Insulin Degludec 100 units · mL−1 in Type 1 Diabetes;Diabetes Care;2020-11-10